Kaj Blennow, MD, PhD, discusses the impact of biomarkers in the changing landscape of AD diagnosis, and how amyloid and tau positron emission tomography imaging and cerebrospinal fluid biomarkers can be used to increase diagnostic certainty when used in tandem with clinical assessment. He also outlines the potential role for blood-based biomarkers in the future diagnostic workup. Throughout, Professor Blennow highlights the importance of including underserved and underrepresented populations in AD biomarker research.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.